|
Bacteriophage Interest Group (BIG)
|
Other
|
FDA
|
NIAID
|
Scientific interest group discussing science and issues around bacteriophage as treatment. Includes members from FDA, BARDA, and DMID
|
|
BARDA-DRIVe (DRIVE)
|
Research Initiative
|
ASPR
|
NIAID
|
BARDA DRIVe funds early stage companies for life saving innovation. Collaboration is on agnostic pathogen detection.
|
|
Behavioral Health Coordinating Council (BHCC) Children and Youth Behavioral Health Subcommittee
|
Committee, Work group, Advisory group, or Task Force
|
ACF, CMS, ACL, AHRQ, FDA, IHS, ASPE, CDC, OASH
|
NICHD, NIMH, NIDA
|
Our initial high-level priorities/areas of focus for children and youth: Ensure children, youth, and caregivers have access to appropriate behavioral health prevention resources, screening, referral, and treatments in their communities, schools, and early education settings; Address behavioral health needs resulting from the COVID-19 pandemic; Advance health equity by addressing the health needs of underserved communities; Support the behavioral health workforce that serves children and youth.
|
|
Behavioral Health Coordinating Council (BHCC) Performance Measures, Data, and Evaluation Subcommittee (MDE)
|
Committee, Work group, Advisory group, or Task Force
|
ACF, ACL, AHRQ, ASA, ASPE, CDC, CMS, FDA, IHS, NIH, ONC, SAMHSA
|
NIDA, NIMH
|
The goal of the Behavioral Health Coordinating Council (BHCC) Performance Measures, Data, and Evaluation Subcommittee (MDE) working group is to ensure that HHS leadership has the data and analyses needed to ensure that behavioral health is incorporated into HHS efforts. The working group will identify data gaps and propose ways to address them.
|
|
Bench to Bedside: Integrating Sex and Gender to Improve Human Health
|
Resource Development
|
FDA
|
OD/DPCPSI/ORWH
|
Bench to Bedside: Integrating Sex and Gender to Improve Human Health was developed in partnership with the Food and Drug Administration (FDA) Office of Women’s Health (OWH). This online course gives users a thorough and up-to-date understanding of sex and gender influences on health and disease so users can apply this knowledge when conducting research and interpreting evidence for clinical practice. Course material showcases examples from basic science through clinical trials and translation into practice to ensure participants understand the importance of considering the influence of sex and gender throughout the research spectrum and beyond. Through its six modules, the course focuses on key health conditions on which sex and gender have an impact. The six modules that compose the course are Immunology, Cardiovascular disease, Pulmonary disease, Neurology, Endocrinology, and Mental Health.
|
|
Best Pharmaceuticals for Children Act (BPCA) Data Monitoring Committee
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NICHD, NCI, NHLBI
|
This group provides safety oversight for all studies conducted under BPCA.
|
|
Best Pharmaceuticals for Children Act (BPCA) Research Oversight Committee
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NICHD, NHLBI, NCI
|
This group provides programmatic support to project lead for the BPCA clinical program which includes the oversight prioritization and concept developments for the Pediatric Trials Network.
|
|
Best Pharmaceuticals for Children Act (BPCA) Working Group
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NICHD, NHLBI, NCI
|
This group provides safety oversight for all studies conducted under BPCA.
|
|
Biodefense Coordination Team (BCT)
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA, OS
|
OD/OSP
|
Coordinates implementation of the U.S. National Biodefense Strategy and Presidential Memorandum on the Support for Biodefense towards an integrated, comprehensive approach to manage biodefense activities in support of the broader biodefense enterprise.
|
|
Biodosimetry Trans-NIH Working Group and Special Journal Issue
|
Committee, Work group, Advisory group, or Task Force
|
ASPR, FDA
|
NIAID
|
This collaboration highlights regulatory and scientific approaches in research and advancement of biodosimetry tests in both NIAID and BARDA portfolios
|